STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Lilly adds to buyout streak with $1.5B purchase of startup Calytrix biopharmadive.com